SOLID TUMOR, ADULT

This study tested a personalized vaccine made from each patient's unique cancer mutations (neoantigens) in 8 adults with advanced solid tumors or high risk of recurrence. The vaccine aims to train the immune system to recognize and attack cancer cells. Researchers checked for saf…

This early-stage study tested a new drug called JNJ-64619178 in 114 people with advanced cancers, including lymphoma and solid tumors. The main goal was to find the safest dose and check for side effects. The drug works by blocking a protein that helps cancer cells grow.

This early-phase trial tested whether adding thiopurine drugs (6-MP and 6-TG) to the immunotherapy atezolizumab could help shrink advanced solid tumors that have a moderate number of genetic mutations. The study enrolled 18 adults with metastatic cancers that had no standard cure…

This early-stage study tested a new drug called DCR-STAT3 in 26 adults with solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. Researchers monitored side effects and how the drug moved through the…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, …

This study tested a drug called HER3-DXd in 63 adults with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining around the brain and spinal cord. The goal was to see if the drug could shrink brain tumors or help patients live longer. Partic…

This study tested a new combination of two drugs (ICT01 and low-dose interleukin-2) in 56 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the combo is safe and can shrink tumors or slow their growth. The trial had two p…

This study tested a new drug called DF9001 in 24 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The main goals were to check safety and find the best dose, both alone and with another…

This early-stage study tested a new oral drug called EVT801 in 32 adults with advanced solid tumours that no longer responded to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. The trial is now complete, and results wil…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. T…

This early-stage study tested a new drug called GEN1056 in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. All participants received GEN1056, and resea…

This early-phase study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find safe doses and check for side effects. The study also looked…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The study looked at safety and how well the drug works, both alone and combined with o…

This study tested a drug called leronlimab in 16 adults with advanced solid tumors that have a specific protein (CCR5+). The main goals were to check safety and see if the drug could slow tumor growth. Participants had already tried other treatments or had no standard options lef…